Funding for this research was provided by:
Agencia Estatal de Investigación (BIO2016-77038-R)
H2020 European Research Council (614944)
Received: 13 May 2020
Accepted: 11 August 2020
First Online: 9 September 2020
Ethics approval and consent to participate
: Mice experiments were conducted following the European Union’s animal care directive (86/609/CEE) and were approved by the Ethical Committee of Animal Experimentation of the Vall d’Hebron Research Institute. Human tumor samples for PDX were obtained after approval from the Ethics Committee of the Vall d’Hebron University Hospital. Written informed consent was signed by all patients. The analysis of patient data was approved by the Memorial Sloan Kettering Cancer Center Institutional Review Board (IRB), and all patients provided written informed consent for tumor sequencing and review of patient medical records for detailed demographic, pathologic, and treatment information. The research conformed to the principles of the Helsinki Declaration.
: Not applicable.
: M.S. has received research funds from Puma Biotechnology, AstraZeneca, Daiichi-Sankio, Immunomedics, Targimmune, and Menarini Ricerche; is a cofounder of ExternalRef removed; and is on the advisory board of Menarini Ricerche. P.R. reports consulting/advisory board for Novartis and institutional research support from Illumina and GRAIL, Inc. S.C. has received research funds in the past from Novartis and Eli Lilly and ad hoc consulting honoraria from Novartis, Sermonix, Context Therapeutics, and Revolution Medicines. The remaining authors declare that they have no competing interests.